Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Dose Study of MK-0616 in Healthy Japanese Participants
jRCT2031210233Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability, Single-dose pharmacokinetics and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2031210233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210233.